Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (114,880)	$ (89,943)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	9,409	4,734
Noncash lease expense	3,597	3,489
Share-based compensation expense	27,041	19,733
Intangible assets amortization	842	842
Investment amortization	1,414	4,174
Research and development inventory reserve	2,769
Other	(19)	(7)
Changes in operating assets and liabilities
Accounts receivable, net	(6,303)	(4,127)
Inventory	(2,284)	(4,549)
Prepaid expenses and other current assets	644	1,995
Accounts payable and accrued liabilities	(8,956)	(2,476)
Operating lease right-of-use assets and liabilities	(715)	4,539
Deferred revenue	(24,174)	(33,742)
Other	97	(120)
Net cash used in operating activities	(111,518)	(95,458)
Investing activities
Purchases of property and equipment	(8,375)	(37,882)
Purchases of marketable securities	(85,191)	(96,352)
Proceeds from maturities of marketable securities	136,000	269,500
Net cash provided by investing activities	42,434	135,266
Financing activities
Proceeds from exercise of stock options	6,739	20,513
Proceeds from initial capital contributions for Digital Biotechnologies, Inc.		429
Net cash provided by financing activities	6,739	20,942
Net (decrease) increase in cash, cash equivalents and restricted cash	(62,345)	60,750
Cash, cash equivalents and restricted cash at beginning of year	141,203	125,574
Cash, cash equivalents and restricted cash at end of period	78,858	186,324
Noncash investing activities
Purchases of equipment included in accounts payable and accrued liabilities	$ 3,286	$ 7,067